More recently, the development of different multiplex strategies by using new biomarkers such as α-methyl CoA-racemase “AMACR”, pAkt and p63 with the conventional histological markers, including high molecular weight cytokeratin “34betaE12”, has given promising results for optimizing conventional screening tests and improving the accuracy of diagnosis and prognosis of PC patients [68]–[71]. The gene discussed is AMACR; the disease is pachyonychia congenita.